Aktis Oncology posts investor presentation on miniprotein radioconjugate platform, lead Nectin-4 and B7-H3 programs

Aktis Oncology, Inc.

Aktis Oncology, Inc.

AKTS

0.00
  • Aktis outlined two clinical radiopharmaceutical programs built on miniprotein radioconjugates, pairing imaging with targeted therapy.
  • Lead asset AKY-1189 targets Nectin-4 tumors; Phase 1b is ongoing with preliminary data expected in 1Q 2027.
  • Second program AKY-2519 targets B7-H3; Phase 1b in mCRPC started in 2Q 2026 with preliminary data expected in 2027.
  • A B7-H3 basket Phase 1b trial is slated to start in 2H 2026, expanding into lung, colorectal, and other solid tumors.
  • Manufacturing scale-up remains a near-term focus, with an in-house GMP suite expected to be operational in 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.